<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="573">
  <stage>Registered</stage>
  <submitdate>24/05/2005</submitdate>
  <approvaldate>24/05/2005</approvaldate>
  <nctid>NCT00111735</nctid>
  <trial_identification>
    <studytitle>Thyroxine Titration Study</studytitle>
    <scientifictitle>What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2003-015</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypothyroidism</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Thyroxine

Treatment: drugs: Thyroxine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual analog scales assessing wellbeing</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>treatment satisfaction score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>treatment preference</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>quality of life scores</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cognitive function tests</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical and biochemical markers of thyroid hormone action</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female subjects &gt;18 years of age

          -  Primary hypothyroidism =6 months duration arising from autoimmune hypothyroidism,
             thyroidectomy or radioiodine treatment

          -  Thyroxine dose =100 mcg/day

          -  No change in thyroxine dose in past 2 months

          -  Serum TSH of 0.1-4.8 mU/L

          -  Adequate contraceptive measures for women of childbearing age</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Major systemic illness affecting quality of life or likely to affect participation in
             the study

          -  Treatment with T3 currently or in past 2 months

          -  History of thyroid cancer requiring suppression of TSH secretion by thyroxine

          -  Ischaemic heart disease  previous myocardial infarction, angina or coronary artery
             revascularisation

          -  Renal failure: serum creatinine &gt;135 micromol/L

          -  Known liver disease with alkaline phosphatase or ALT &gt;2x upper limit of reference
             range

          -  Bony fracture in past 3 months or Pagets disease of bone

          -  Secondary (central) hypothyroidism or hypopituitarism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to examine the effects of fine titration of thyroxine dosage on
      symptoms of hypothyroidism, wellbeing and quality of life. The hypothesis is that symptoms of
      hypothyroidism, wellbeing and quality of life will be improved in thyroxine-treated subjects
      when serum thyrotropin (TSH) is suppressed and/or in the lower reference range, compared to
      when TSH is in the upper reference range.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00111735</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>